Key result
Nephrologists favor digitoxin in terminal renal failure due to stable pharmacokinetics despite altered renal function.
Why the study?
No consensus has been reached regarding the indications for digitalis therapy in patients with terminal renal failure and cardiac dysfunction.
No takes yet. Share an insight, caveat, or question.
Digitoxin may be favored in terminal renal failure; leaves open prospective validation of dosing adjustments.
Rambausek et al. (2008) conducted a review in Chronic Renal Insufficiency. Digitalis therapy was evaluated. In patients with terminal renal failure, pharmacokinetics of digitalis steroids are altered, and most nephrologists favor digitoxin due to its insensitivity to changes in renal function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: